Meetings - The ASCO Post

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown antitumor activity in a number of cancers, including those of the esoph...

breast cancer

By The ASCO Post Staff / EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

EORTC-NCI-AACR: Genomic Testing in Breast Cancer May Enhance Personalized Treatment: Update of I-SPY 2

New results from the long-running I-SPY 2 trial, which aimed to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, demonstrated the usefulness of two...

hepatobiliary cancer

gastrointestinal cancer

By The ASCO Post Staff / EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

EORTC-NCI-AACR: Dabrafenib Plus Trametinib Active in Some BRAF V600E–Mutated Gastrointestinal Cancers

In a late-breaking presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Zev Wainberg, MD, reported on results from a phase II international clinical t...

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

EORTC-NCI-AACR: Investigational Anti-HER2 Therapy in HER2-Expressing Solid Tumors

EORTC-NCI-AACR: Genomic Testing in Breast Cancer May Enhance Personalized Treatment: Update of I-SPY 2

EORTC-NCI-AACR: Dabrafenib Plus Trametinib Active in Some BRAF V600E–Mutated Gastrointestinal Cancers

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer